cargo-logo-full-color-rgb-1165px@300ppi.jpg
CARGO Therapeutics Announces Appointment of Ginna Laport, MD, as Chief Medical Officer
October 17, 2023 09:05 ET | CARGO Therapeutics, Inc.
— Accomplished clinical leader with significant expertise in hematology/oncology drug development and a track record of advancing multiple modalities of cancer therapeutics — SAN MATEO, Calif., Oct. ...
cargo-logo-full-color-rgb-1165px@300ppi.jpg
CARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific Officer
September 12, 2023 09:05 ET | CARGO Therapeutics, Inc.
– Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage development – SAN MATEO, Calif., Sept. 12, 2023 (GLOBE...
cargo-logo-full-color-rgb-1165px@300ppi.jpg
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors
August 24, 2023 09:05 ET | CARGO Therapeutics, Inc.
– Board of Director appointments follow the Company’s recent launch and $200 million Series A financing in March 2023 – – Appointments include industry veterans John Orwin as Chairman, David Lubner...
cargo-logo-full-color-rgb-1165px@300ppi.jpg
CARGO Therapeutics to Present at the Jefferies Global Healthcare Conference 
May 31, 2023 09:05 ET | CARGO Therapeutics, Inc.
SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced that...
cargo-logo-full-color-rgb-1165px@300ppi.jpg
CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies
March 01, 2023 09:30 ET | CARGO Therapeutics, Inc.
– Series A financing co-led by Third Rock Ventures, RTW and Perceptive Xontogeny Venture Fund, and includes new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management,...